Published online Apr 6, 2021. doi: 10.12998/wjcc.v9.i10.2228
Peer-review started: January 12, 2021
First decision: January 24, 2021
Revised: January 31, 2021
Accepted: February 24, 2021
Article in press: February 24, 2021
Published online: April 6, 2021
Processing time: 77 Days and 6.5 Hours
Highly effective therapeutic treatment against bacterial infection is very important for the prevention and control of infection in burn patients. It is important to monitor the distribution of pathogens, the characteristics and profiles of pathogenic bacteria, and drug resistance in pathogenic bacteria in burn patients for the rapid and accurate selection of antibacterial regimens in clinical practice.
To provide useful and valuable scientific evidence and information for the development of new and effective strategies for the prevention, control, and treatment of bacterial infections in burn patients.
To develop more effective clinical strategies and techniques for the prevention and treatment of bacterial infections in burn patients.
Clinical samples with positive bacteria were collected from patients at the burn ward in Beijing Jishuitan Hospital in China between January 2006 and December 2019. The samples were retrospectively analyzed, the distribution of pathogenic bacteria was determined, and the trends and changes in bacterial drug resistance during different periods were assessed. Drug resistance in several main pathogenic bacteria from 2006 to 2011 and from 2012 to 2019 was comparatively summarized and analyzed.
We analyzed data obtained from samples collected between 2006 and 2019 from 17119 patients. Staphylococcus aureus (21.68%), Pseudomonas aeruginosa (14.23%), Staphylococcus epidermidis (9.61%) were the top three pathogens most frequently isolated from patients.
The circumstantial detection and detailed monitoring of the intensity and growth of different pathogenic bacteria in clinical patients as well as tests of drug sensitivity during burn recovery are particularly important to provide guidelines for the use of antibiotics and other related drugs.
Bacterial specimens should be subjected to more detailed in-depth molecular identification and homology analysis.